Norges Bank
EGRX

Norges Bank’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Norges Bank’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,700
Closed -$227K – 2045
2023
Q2 		$227K Hold
11,700
– – ﹤0.01% 1991
2023
Q1 		$332K Sell
11,700
-300
-3% -$8.91K ﹤0.01% 2065
2022
Q4 		$351K Hold
12,000
– – ﹤0.01% 2105
2022
Q3 		$317K Buy
+12,000
New +$440K ﹤0.01% 2065
2021
Q2 		– Sell
-85,141
Closed -$3.55M – 2269
2021
Q1 		$3.55M Sell
85,141
-87,033
-51% -$4.04M ﹤0.01% 1950
2020
Q4 		$8.02M Sell
172,174
-11,246
-6% -$526K ﹤0.01% 1810
2020
Q3 		$7.79M Sell
183,420
-35,517
-16% -$1.55M ﹤0.01% 1789
2020
Q2 		$10.5M Sell
218,937
-4,800
-2% -$239K ﹤0.01% 1702
2020
Q1 		$10.3M Sell
223,737
-24,442
-10% -$1.23M ﹤0.01% 1603
2019
Q4 		$14.9M Hold
248,179
– – ﹤0.01% 1677
2019
Q3 		$14M Hold
248,179
– – ﹤0.01% 1654
2019
Q2 		$13.8M Hold
248,179
– – ﹤0.01% 1683
2019
Q1 		$12.5M Sell
248,179
-23,568
-9% -$1.05M ﹤0.01% 1723
2018
Q4 		$10.9M Buy
271,747
+96,546
+55% +$4.98M ﹤0.01% 1702
2018
Q3 		$12.1M Buy
175,201
+25,393
+17% +$1.93M ﹤0.01% 1760
2018
Q2 		$11.3M Buy
149,808
+58,691
+64% +$3.69M ﹤0.01% 1772
2018
Q1 		$4.8M Hold
91,117
– – ﹤0.01% 1905
2017
Q4 		$4.87M Buy
91,117
+18,404
+25% +$1.02M ﹤0.01% 1874
2017
Q3 		$4.34M Sell
72,713
-64,364
-47% -$3.89M ﹤0.01% 1885
2017
Q2 		$10.8M Buy
137,077
+21,463
+19% +$1.76M ﹤0.01% 1708
2017
Q1 		$9.59M Buy
115,614
+44,606
+63% +$3.32M ﹤0.01% 1749
2016
Q4 		$5.63M Hold
71,008
– – ﹤0.01% 1839
2016
Q3 		$4.75M Buy
+71,008
New +$3.93M ﹤0.01% 1879

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank's EGRX Position: Q3 2023 in Review

Norges Bank sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 11,700 shares — an estimated $227K sold.

Norges Bank first reported a position in EGRX in Q3 2016 and held it in 23 quarters. The position peaked at $14.9M in Q4 2019. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Norges Bank reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Norges Bank sold 11,700 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $227K.
  • Norges Bank first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 23 quarters.
  • Norges Bank's Eagle Pharmaceuticals, Inc. position peaked at $14.9M in Q4 2019.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.